1[1]Cortesi E, Ramponi S, Corona M, et al. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15. Lung Cancer, 2001,31(2-3)∶271-276.
2[2]Schiller JH, Harrington D, Sandler A, et al. A randomized phase Ⅲ trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol,2000,19∶1A.
3[3]Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase Ⅲ study of the Italian Lung Cancer Project. J Clin Oncol,1999,17(11)∶3522-3530.
4[4]Van Kooten M, Rosenberg J, Morero R, et al. Phase Ⅱ study of gemcitabine plus cisplatin as induction regimen for patients with stage ⅢA-ⅢB non-small-cell lung cancer (abstract 2028). Proc Am Soc Clin Oncol,1999,18∶526A.
5[5]Pesek M, Eliasova B, Certikova G. Gemcitabine and cisplatin as first line therapy in non-small cell lung cancer: preliminary Czech experience. Ann Oncol,1998,9(Suppl 4)∶A465.
2Gebbia V,Oniga F,Agueli R,et al.Treatment of advanced non-small cell lung cancer:chemotherapy with or without cisplatin?[J].Ann Oncol,2006,17(Suppl 2):ii83-ii87.
